New Port Reduces Occurrence of Blood Clots

Published date : 21 August 2013
Article date : 21 August 2013

Poststar.com reports that the FDA has approved AngioDynamic's BioFlo Port. The device is inserted under the skin of patients where frequent or prolonged access to the cardiovascular system is needed for treatments such as chemotherapy.
 
They say that the BioFlo Port, similar to AngioDynamic's BioFlo catheter line, has been shown to greatly reduce the occurrence of blood clots. Apparently, the BioFlo Port reduces such clotting by some 96% compared with non-coated conventional port catheters. Anti-thrombus technology is incorporated into the material from which it is manufactured whilst other devices use coatings or drug-eluting materials that show reduced efficacy over time.
 
AngioDynamics will launch the new ports next year.
 
Source: Poststar.com
 
 
Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.